May 22nd 2025
Patients with extensive-stage small cell lung cancer (SCLC) experienced clinically meaningful benefits with lurbinectedin plus atezolizumab vs atezolizumab in the phase 3 IMforte trial, according to findings being presented at the ASCO Annual Meeting.
Watch the series now!
Diabetes, Cancer Interviews Among Most-Watched Videos of 2018
Dr Michael Kolodziej Reflects on OCM and What Might Come After
Dr Sibel Blau Discusses Physician, Staff Education Around OCM
Using Cost Variation to Identify Savings Opportunities Under the OCM